The anaphase-promoting complex or cyclosome (APC/C) initiates mitotic exit by ubiquitylating cell-cycle regulators such as cyclin B1 and securin. Lys 48-linked ubiquitin chains represent the canonical signal targeting proteins for degradation by the proteasome, but they are not required for the degradation of cyclin B1. Lys 11-linked ubiquitin chains have been implicated in degradation of APC/C substrates, but the Lys 11-chain-forming E2 UBE2S is not essential for mitotic exit, raising questions about the nature of the ubiquitin signal that targets APC/C substrates for degradation. Here we demonstrate that multiple monoubiquitylation of cyclin B1, catalysed by UBCH10 or UBC4/5, is sufficient to target cyclin B1 for destruction by the proteasome. When the number of ubiquitylatable lysines in cyclin B1 is restricted, Lys 11-linked ubiquitin polymers elaborated by UBE2S become increasingly important. We therefore explain how a substrate that contains multiple ubiquitin acceptor sites confers flexibility in the requirement for particular E2 enzymes in modulating the rate of ubiquitin-dependent proteolysis.
to target the protein for degradation by the proteasome 11 . In this context, Lys 48-linked ubiquitin polymers are dispensable for binding of modified cyclin B1 to ubiquitin receptors and degradation by the proteasome 11 . More recent work indicates that the assembly of a proteolytic signal on APC/C substrates may occur in two stages. In budding yeast, Ubc4 initiates ubiquitin conjugation, whereas Ubc1 elongates ubiquitin chains 27 . Similarly, in metazoans, UBCH10 has been proposed to initiate monoubiquitylation of the substrate, followed by UBE2S-dependent extension of Lys 11-linked ubiquitin chains 7, 8, 10 . Consistent with this idea, depletion of UBE2S from Drosophila S2 cells prolongs metaphase and stabilizes cyclin B1 at the spindle poles 7 . In contrast, UBE2S is not essential for normal mitosis in human HeLa cells, but rather may be important for proteolysis under conditions where APC/C activity is compromised, such as during recovery from druginduced spindle-assembly checkpoint activation 8 . Using an approach in which Xenopus extracts are made dependent on exogenous ubiquitin, we sought to understand whether APC/C-catalysed proteolysis requires Lys 11 or other ubiquitin linkages to efficiently degrade cyclin B1.
RESULTS

Inhibiting ubiquitin-chain formation has only a modest effect in stabilizing cyclin B1 in Xenopus extract
To quantitatively evaluate the role of different ubiquitin-chain linkages in targeting cyclin B1 for degradation in mitotic Xenopus extracts, we measured the degradation of a purified, 35 S-labelled amino-terminal fragment of human cyclin B1 (cycB1-NT), which was degraded in an APC/C-and proteasome-dependent manner ( Supplementary Fig. S1a-d ). Using ubiquitin absolute quantification (AQUA) measurements 11, 28 , we calculated that free ubiquitin is present at 5-10 µM concentration in Xenopus extracts (D.K. and N.H., unpublished observations). When added at 44 µM or 116 µM final concentration, wild-type ubiquitin and different ubiquitin mutants containing a single lysine-to-arginine substitution at position 11, 48 or 63, or at all three positions simultaneously (Ub triR ), stimulated cycB1-NT proteolysis, albeit with different kinetics ( Supplementary Fig. S1e,f) . These results were unexpected, as mass spectrometric analysis indicated that elimination of all three principal sites of ubiquitin-ubiquitin linkage by the APC/C rendered ubiquitin incapable of forming ubiquitin chains in reconstituted reactions ( Supplementary Fig. S2 ).
In contrast, addition of methylated ubiquitin (Ub me ) was slightly inhibitory. These findings indicate that ubiquitin levels are limiting for proteolysis, and raise the question of whether ubiquitin chains are essential for cyclin B1 degradation in Xenopus extract. We next sought to make Xenopus extracts dependent on exogenous ubiquitin by inhibiting ubiquitin recycling. Pre-treatment of extracts with ubiquitin vinyl sulfone (UbVS), a general inhibitor of ubiquitin isopeptidases 29 , inhibited cyclin proteolysis in a dose-dependent manner, such that 20 µM UbVS inhibited degradation by 90-95% ( Supplementary Fig. S3a ). Degradation was fully restored by addition of 44 µM wild-type ubiquitin with partial rescue observed at lower concentrations ( Fig. 1a ). Concentrations of UbVS greater than 20 µM dampened the ability of 44 µM wild-type ubiquitin to restore degradation ( Supplementary Fig. S3b ). Mutations that interfere with recognition of ubiquitin by proteasome receptors (L8A, I44A or V70A; refs 30-32) hampered its ability to support proteolysis ( Fig. 1b) . In contrast, mutations that interfere with the non-proteolytic functions of ubiquitin (F4A (refs 33,34) or D58A (refs 35,36) ) had no effect on its ability to stimulate degradation ( Fig. 1b ). UbVS treatment led to loss of ubiquitylated species in the extract ( Fig. 1c ) and near complete discharge of E2 ∼ ubiquitin thioesters ( Fig. 1d ,e); both effects were reversed following addition of exogenous ubiquitin.
We next examined the ability of chain-terminating ubiquitin mutants to rescue degradation in UbVS-treated extracts. Addition of wild-type ubiquitin, Ub 48R and Ub 63R rescued degradation efficiently, showing a half-life of approximately 15 min ( Fig. 2a ). After 20 min, the rate of degradation slowed, probably a consequence of ubiquitin depletion in the UbVS-treated extract, as supplementation with additional ubiquitin restored degradation to the initial rate ( Fig. 2b ). Extracts supplemented with Ub 11R or Ub triR degraded substrate with surprisingly fast kinetics. Even addition of Ub me (Fig. 2c ) or a lysine-less ubiquitin (Ub K0 ; Supplementary Fig. S3c ) supported degradation, with a half-life of approximately 30 min. We next assessed how constraining the topology of ubiquitin chains to a single lysine residue affected degradation of cycB1-NT ( Fig. 2c ). Addition of Ub K11only or Ub K48only to UbVS-treated extract restored cycB1-NT proteolysis, but with slower kinetics when compared with wild-type ubiquitin. As mutation of Lys 6 of ubiquitin may have an inhibitory effect on proteasomal degradation 37 , we examined the effect of restricting chain formation to one of the three principal sites of ubiquitin-ubiquitin attachment mediated by UBCH10 by mutating the remaining two ( Supplementary Fig. S2 ). Ub (48+63)R stimulated degradation efficiently, consistent with the ability of Lys 11 linkages to support degradation ( Fig. 2d ). Ubiquitin forms supporting Lys 48 and Lys 63 linkages (Ub (11+63)R and Ub (11+48)R , respectively) and Ub triR supported proteolysis with slightly slower kinetics. Together these findings indicate that the ability to construct Lys 11-linked chains provides a kinetic advantage for degradation, but the advantage is modest. In principle this advantage could arise from the utilization of Lys 11 in chain-forming reactions catalysed by UBCH10, or from a role of UBE2S, which elongates ubiquitin chains exclusively through Lys 11 linkages.
Ubiquitin chains are required for cyclin B1 degradation only when the number of available lysine residues in cyclin B1 is restricted
Cyclin B1 contains 18 lysine residues in its unstructured N-terminal region upstream of the cyclin box; 15 of these lysine residues are located within the first 88 amino acids close to the destruction box ( Fig. 3a ). To rule out the possibility that our results were influenced by use of an N-terminal fragment of cyclin B1, we first examined proteolysis of full-length wild-type cyclin B1 in UbVS-treated extracts ( Fig. 3c ). Addition of Ub 11R or Ub triR stimulated degradation, albeit at slightly reduced rates relative to wild-type ubiquitin. Ub me also supported degradation of cyclin B1, although a small fraction of the protein accumulated in a triply ubiquitylated species. To examine whether reducing the number of lysines in cyclin B1 renders its proteolysis dependent on ubiquitin-chain formation, we measured degradation of cyclin B1 mutants that contained either one or four lysine residues in the first 115 amino acids only at position 64 (cyc K64only ) or at positions 59, 63, 64 and 67 (cyc K59,63,64,67only ). We chose these positions as mass spectrometry studies indicated that these lysine residues become ubiquitylated early in the course of reconstituted ubiquitylation reactions (D.K. and N.H., unpublished observations). Cyc K64only was degraded rapidly in untreated Xenopus extract, and was fully stabilized in UbVS-treated extract ( Fig. 3c ). However, unlike the case for wild-type cyclin B1, Ub 11R did not support efficient degradation of cyc K64only . Similar results were obtained with Ub triR and Ub me , with the latter causing quantitative accumulation of cyclin B1 in a monoubiquitylated form. Restoration of three additional lysine residues in cyclin B1 (cyc K59,63,64,67only ) partially rescued its degradation in UbVS-treated extracts supplemented with Ub me (Fig. 3d ). We conclude that when deubiquitylating enzymes are inhibited, the attachment of single ubiquitin molecules to multiple lysine residues in cyclin is sufficient to target the substrate for degradation. Strict dependence on elaboration of ubiquitin chains seems to occur only when the number of available substrate lysines is restricted.
cyc K59,63,64,67only 
Multiple monoubiquitylation can target cyclin B1 for efficient degradation in a reconstituted system and in Xenopus extract
We next assessed whether the effects of ubiquitin mutants on proteolysis paralleled effects on ubiquitin conjugation in reconstituted ubiquitylation reactions. Elimination of Lys 48 or 63 of ubiquitin had no effect on the mass of conjugates generated by UBCH10, whereas elimination of Lys 11 reduced the mass of conjugates, consistent with the previously reported preference of UBCH10 for synthesizing Lys 11 ubiquitin-ubiquitin linkages 6, 11 (Fig. 4a ). In the presence of ubiquitin types that do not support ubiquitin polymer assembly (Ub triR and Ub me ), the maximal extent of substrate modification (5-6 ubiquitins per cyclin B1 molecule) was observed at early time points and remained unchanged in longer reactions ( Fig. 4a) , implying that only a subset of the 18 lysine residues in the cyclin B1 N-terminal domain become ubiquitylated. A time course analysis of ubiquitylation with either wild-type ubiquitin or Ub triR (Fig. 4b ) revealed that the conjugation of ubiquitin monomers to distinct lysines in cyclin B1 occurs with rapid kinetics. Furthermore, conjugates bearing 4 or more ubiquitin moieties were capable of binding proteasome-associated ubiquitin-receptors [38] [39] [40] [41] [42] [43] [44] [45] [46] including Rpn10 ( Fig. 4c,d ) and Rad23 (Fig. 4e ,f). For conjugates of a similar molecular mass, substrate ubiquitylated with Ub triR bound to receptors more efficiently than substrate ubiquitylated with Ub me , indicating that methylation of ubiquitin may compromise its affinity for ubiquitin receptors. We found similar binding patterns with cyclin B1-ubiquitin conjugates generated with UBC4 as the E2 (data not shown). Together these results indicate that multiple monoubiquitylation occurs rapidly and can result in a productive signal for binding ubiquitin receptors. We next sought to determine whether multiple monoubiquitylation can target cyclin B1 for degradation in a reconstituted system. Full-length cyclin B1 in complex with CDK1 was ubiquitylated with either UBCH10 or UBC4, in conjunction with wild-type or mutant ubiquitin. The resulting conjugates were incubated with purified human proteasomes that were washed with high salt concentrations to eliminate USP14, a deubiquitylating enzyme that can antagonize cyclin B1 degradation in vitro 47, 48 . These proteasomes, which retain the deubiquitylating enzymes RPN11 and UCH37 (ref. 47) , rapidly degraded polyubiquitylated cyclin B1 generated with UBCH10 ( Fig. 5a ) or UBC4 ( Fig. 5b ). Conjugates formed with Ub triR or Ub K0 were efficiently degraded, whereas those generated with Ub me were degraded less rapidly, consistent with the defect in the ability of these conjugates to bind ubiquitin receptors ( Fig. 4c,e ). Similar results were obtained in a quantitative assay using radiolabelled full-length cyclin B1 15 min 90 min Ub type ( Supplementary Fig. S4 ). Degradation of cyclin B1 in the reconstituted system was confirmed to be both APC/C and ubiquitin dependent (Supplementary Figs S4 and S5c). Similar experiments with radiolabelled cycB1-NT pre-ubiquitylated by UBCH10 ( Fig. 5c ) revealed that that degradation of multiply monoubiquitylated cyclin B1 was sensitive to addition of the deubiquitylating enzyme USP14 (Fig. 5d ). This effect was reversed by IU1, an inhibitor of the catalytic activity of USP14 ( Supplementary Fig. S5 ; ref. 47 ). Together these results indicate that purified proteasomes can efficiently degrade multiply monoubiquitylated cyclin B1 and that USP14 can deubiquitylate this substrate to suppress degradation.
To determine whether multiple monoubiquitylation can target cyclin B1 for degradation under physiological conditions in the presence of active deubiquitylating enzymes, we added the ubiquitylated species analysed in Fig. 5c to interphase Xenopus extract, a state in which the APC/C is inactive ( Fig. 5e ). Conjugates generated with wild-type ubiquitin or Ub triR were efficiently degraded, whereas conjugates generated with Ub me were degraded less efficiently. Similar results were obtained when the ubiquitin conjugates were introduced into extracts supplemented with excess non-ubiquitylated unlabelled competitor to prevent additional APC/C-mediated ubiquitylation ( Supplementary  Fig. S6b ,c) or to extracts that had been immunodepleted of APC/C ( Supplementary Fig. S6f ). Pre-treatment with UbVS, at a concentration identical to that used to deplete free ubiquitin, did not accelerate degradation of conjugates ( Fig. 5e ). Similarly, addition of an inhibitor of USP14, IU1, failed to accelerate degradation of cyclin B1 in Xenopus extracts ( Supplementary Fig. S7 ). Together these findings indicate that Xenopus extracts can rapidly degrade cyclin B1 bearing multiple ubiquitin monomers attached to distinct lysine residues.
Analysis of the role of UBE2S in cyclin B1 degradation
The ability of Ub 11R and chain-terminating ubiquitins to support proteolysis raised a question as to whether the E2 enzyme UBE2S is required for cyclin B1 degradation in Xenopus extract. We therefore immunodepleted the protein and measured how this affected cyclin degradation. Antibodies efficiently depleted the UBE2S protein, as observed by the absence of signal following 25-fold enrichment of E2 enzymes on ubiquitin agarose ( Fig. 6a ), without affecting levels of the APC/C or the E2 UBCH10 ( Fig. 6a ). UBE2S depletion caused only a slight increase in the half-life of cycB1-NT as compared with control-depleted extract (Fig. 6b ), which was reversed by adding back 10 nM of the recombinant enzyme. We reasoned that UBE2S is not essential for rapid degradation of cyclin B1 because the substrate contains multiple lysine residues that can serve as sites of attachment of short ubiquitin chains. We therefore examined the effect of UBE2S depletion on the rate of degradation of cyc K64only compared with that of wild-type cyclin B1 (Fig. 6c ). Degradation of full-length wild-type cyclin B1 was unaffected by depletion of UBE2S, but proteolysis of cyc K64only was highly sensitive to the depletion of UBE2S, and addition of recombinant UBE2S fully restored degradation ( Fig. 6c ). Together these findings indicate that UBE2S is present in Xenopus extract at sufficient levels to support cyclin proteolysis, but becomes essential only when the number of ubiquitylatable lysine residues in cyclin B1 is restricted. Similarly, we found that immunodepletion of UBCH10 ( Supplementary Fig. S8a ) had a modest effect on degradation of wild-type cyclin B1, but more significantly delayed turnover of cyc K64only ( Supplementary Fig. S8b ). The delay in degradation of cyc K64only was rescued by addition of 50 nM of recombinant UBCH10. These findings indicate that other E2 enzymes in the extract may be sufficient to support APC/C-dependent degradation of cyclin B1 in Xenopus extracts. Enzymes of the UBC4/5 class are the best candidates for such a role, but we were unable to identify an antibody that could efficiently deplete endogenous UBC4/5 and thus could not evaluate their role in cyclin B1 degradation. The APC/C and the E2 UBCH10 collaborate to transfer ubiquitin monomers to multiple lysine residues on cyclin B1, with subsequent elaboration of short ubiquitin chains containing Lys 63, Lys 48 and Lys 11 linkages, with Lys 11 linkages predominating 11 . On achievement of a threshold of ubiquitin mass, which seems to be 4-5 ubiquitin monomers, multiply monoubiquitylated substrate can associate with proteasome-associated ubiquitin receptors and be degraded efficiently. However, when the number of lysine residues in cyclin B1 is restricted, ubiquitylation catalysed by UBCH10 is insufficient for rapid proteolysis and the activity of UBE2S in extending Lys 11-linked ubiquitin polymers becomes important for efficient degradation.
DISCUSSION
Here we have evaluated the role of ubiquitin-chain topology in targeting cyclin B1 for degradation. Our study was motivated by recent findings indicating that Lys 11 linkages, mediated by the chainforming E2 enzyme UBE2S, may be important for APC/C-dependent proteolysis. However, our earlier work indicated that APC/C, solely in conjunction with the E2 enzyme UBCH10 or the enzyme UBC4/5, can build a ubiquitin signal that is sufficient for degradation by purified proteasomes 11 . Here we provide a resolution to this paradox, demonstrating that conjugation of ubiquitin to multiple lysine residues of cyclin B1 provides an alternative degradation signal for cyclin B1 that does not require chain extension by the Lys 11-specific E2 UBE2S. Lys 11-linked ubiquitin-chain formation becomes essential only when the number of available lysine residues in cyclin B1 is restricted. Dominant-negative effects of different ubiquitin types may be difficult to observe when examined in a background that contains wild-type ubiquitin. By inhibiting ubiquitin recycling, we were able to impose a state of ubiquitin deficiency in extract sufficient to stabilize cyclin B1. The strong dependence of cyclin proteolysis on ubiquitin availability has not been previously appreciated, and supports the possibility that control of ubiquitin availability could regulate the rate of APC/C substrate degradation. Addition of ubiquitin fully rescues cyclin degradation in UbVS-treated extracts, but the rate of cyclin degradation is no faster in a UbVS-treated extract relative to a non-treated extract. This finding indicates that for deubiquitylating enzymes to be able to antagonize degradation, it may be crucial that the rate of ubiquitylation be constrained by limiting the availability of free ubiquitin.
The UbVS system enabled us to define the role of different chain linkages in targeting substrates for degradation by the proteasome. In agreement with earlier work in a reconstituted system 11 , Lys 48 ubiquitin linkages were not required for efficient cyclin proteolysis in UbVS-treated extract. Surprisingly, in the light of recent studies 6,7,10 , ubiquitin incapable of forming Lys 11 linkages (Ub 11R ) also supported efficient degradation of cyclin B1. Importantly, we found that chainterminating ubiquitins (Ub triR and lysine-less ubiquitin) also supported robust rates of cyclin proteolysis. Ub me was less capable of supporting rapid degradation, which may reflect less efficient recognition by ubiquitin receptors and the proteasome due to modification of Lys 6 of ubiquitin 37 . However, on restriction of ubiquitylation to a single lysine residue in cyclin as in cyc K64only , chain-terminating ubiquitins were no longer able to support substrate degradation. Together these findings indicate that ubiquitin-chain formation may not be essential for cyclin proteolysis unless the number of available lysine residues is restricted.
We propose that attachment of monoubiquitin to multiple lysines in cyclin B1 has the potential for generating a high density of ubiquitin that promotes receptor binding (Fig. 6d ). In such an arrangement, the hydrophobic patches on distinct ubiquitin units may be able to engage multiple ubiquitin receptors. Multiply monoubiquitylated cyclin B1 thus resembles a ubiquitin chain, except that the cyclin B1 polypeptide chain is used as a backbone to link one ubiquitin molecule to another. Whether particular spacing of ubiquitylated lysine residues is essential for recognition by ubiquitin receptors remains unknown. In our pulldown experiments, there may be some enhanced avidity resulting from a dimeric glutathione-S-transferase (GST) moiety positioning two ubiquitin-associated domains in close proximity 49 . However, the ability of the multiply monoubiquitylated protein to be degraded by purified proteasomes and in Xenopus extracts indicates that this substrate must have sufficient affinity for proteasome-associated ubiquitin receptors to support proteolysis.
The capacity of purified proteasomes to rapidly degrade multiply monoubiquitylated cyclin B1 was significantly suppressed by USP14, indicating that USP14 can efficiently remove monoubiquitin, as well as trim ubiquitin chains. However, USP14 does not seem to strongly antagonize proteasome function in Xenopus extract, as treatment of extract with UbVS or the USP14-specific inhibitor IU1 did not appreciably enhance turnover of pre-ubiquitylated cyclin. Although present in Xenopus extracts (N.V.D. and R.W.K., unpublished data), levels of USP14 associated with proteasomes in extract may be insufficient to impede proteolysis. Together, these findings indicate that the proteasome does not impose a requirement for ubiquitin-chain formation for efficient proteolysis of cyclin B1 in Xenopus extract. Our study further strengthens the view that the proteasome has the capacity to recognize and degrade substrates bearing ubiquitin modifications distinct from the canonical Lys 48linked polyubiquitin chains 4,50-53 .
Although UBE2S is sufficient to elongate Lys 11-linked ubiquitin chains to promote the degradation of APC/C substrates 7-10 , we found that UBE2S depletion of Xenopus egg extract had no impact on degradation of wild-type cyclin B1. Our findings are consistent with the report that UBE2S is largely dispensable for cyclin B1 degradation in unperturbed mitosis in human cells 8 . The lack of requirement for UBE2S and Lys 11-linked ubiquitin chains for robust degradation of cyclin B1 in the Xenopus system may be a consequence of higher levels of UBCH10 than seen in other biological contexts 7, 8 . Furthermore, the relative importance of UBCH10 and UBE2S in degradation of different APC/C substrates may vary. Human cyclin B1 is lysine rich in its N-terminal domain, containing 18 lysine residues, whereas cyclin A2 has 12 lysine residues in the same region, which may make the latter protein more dependent on the chain-elongating enzyme UBE2S for degradation. Similarly, Saccharomyces cerevisiae Clb2 is relatively lysine poor in its N-terminal domain, containing only 6 lysine residues, potentially explaining the importance of a chain-elongating E2 in this system 27 . A greater dependence on chain-elongating E2s may impact the sensitivity of different substrates to deubiquitylation. In this regard, cyclin A2 degradation during interphase is specifically impeded by the deubiquitylating enzyme USP37 (ref. 54) , but this enzyme does not seem to antagonize cyclin B1 degradation. An interesting future question is how the balance between multiple monoubiquitylation and ubiquitin-chain formation affects sensitivity of degradation to deubiquitylating enzymes. Finally, our work raises the possibility that the degree of dependence on UBE2S could be regulated by posttranslational modification of the substrate. For example, acetylation is known to affect degradation of the spindle-checkpoint protein BubR1 (ref. 55) . By restricting the number of ubiquitylatable lysine residues, acetylation could increase the dependence of degradation pathways on UBE2S-catalysed chain formation.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturecellbiology Note: Supplementary Information is available on the Nature Cell Biology website METHODS Antibodies and reagents. Proteins were separated by SDS-PAGE on NuPAGE 4-12% or 12% Bis-Tris gels (Invitrogen), followed by wet transfer to PVDF. Sources of antibodies for immunoblotting were as follows: anti-cyclin B1 (Ab-2; RB-008-P, Neomarkers), anti-Cdc27 (610455, BD Transduction Laboratories), anti-UBCH10 (A-650, Boston Biochem; AB3861, Millipore), anti-UBE2S (N-14; sc-131354, Santa Cruz Biotechnology), anti-UBCH5 (A-615; Boston Biochem), anti-ubiquitin (P4D1; sc-8017; Santa Cruz Biotechnology). Secondary antibodies included anti-goat IgG-HRP (sc-2020; Santa Cruz Biotechnology); anti-rabbit IgG-HRP (NA934) and anti-mouse IgG-HRP (NA931) were from GE Healthcare. Antibodies for immunoprecipitation or immunodepletion included: anti-Cdc27 (AF3.1; sc-9972) and anti-UBE2S (N-14; sc-131354) from Santa Cruz Biotechnology; anti-UBCH10 (gift from H. Yu, UT Southwestern, USA); and for control depletions, normal rabbit (sc-2027) and normal goat (sc-2028) IgG, both from Santa Cruz Biotechnology. UBE2S antibodies were coupled to UltraLink immobilized protein A/G beads (53132, Pierce). UBCH10 and CDC27 antibodies were coupled to Affiprep protein A beads (156-0006, Bio-Rad). Ubiquitin agarose (U-405), UbVS (U-202), MG262 (I-120), Ub me and ubiquitin mutants except for Ub (11+48)R , Ub (11+63)R and Ub triR were purchased from Boston Biochem. TAME (T4626) and ubiquitin (U6253) were purchased from Sigma.
Preparation of recombinant proteins. Ubiquitin mutants Ub (11+48)R , Ub (11+63)R
and Ub triR were generated by introducing arginine codons (AGA, AGG) through PCR-mediated mutagenesis of the human ubiquitin sequence (cloned in pET3a). Plasmids were verified by sequencing and the purified proteins analysed by mass spectrometry. To ensure efficient arginine incorporation, BL21(DE3) cells were co-transformed with pJY2 (refs 56), which carries T7 lysozyme (LysS) and a gene encoding tRNA Arg UCU . Cultures were grown at 37 • C to an attenuance (D) of ∼0.5 at 600 nm, and induced with 100 µM IPTG at D 600 nm = 0.6 at 25 • C for 5 h. Cells were ruptured by sonication in QA lysis buffer (50 mM HEPES (pH 7.7), 100 mM KCl, protease-inhibitor cocktail, 5 mM 2-mercaptoethanol and 10 µg ml −1 DNase), lysozyme was added to 1 mg ml −1 concentration, and incubated with rotation at 4 • C for 15 min. Following sonication, cell lysates were clarified by centrifugation and the resulting supernatants applied to a Q column. The flow-through containing ubiquitin was concentrated and purified by size-exclusion chromatography. Fractions containing ubiquitin were typically >95% pure.
To generate full-length cyclin B1-CDK1 complex, human cyclin B1 and CDK1 baculoviruses were used as described previously 11 . To generate mutants of cyclin B1, DNA fragments encoding the N-terminal 124 amino acids of wild-type human cyclin B1 (5 -AACCGGTCCGAAACCGTCGACATGTCGCATCACCAT-CACCATCACGGCTCGATGGCGCTCCGAGTCACGCGTAACTCGAAAATTAA-TGCTGAAAATAAAGCGAAAATCAACATGGCAGGCGCCAAGCGCGTTCCTA-CGGCACCGGCGGCAACCTCCAAACCCGGGCTGAGGCCAAGAACAGCTCT-TGGGGACATTGGTAACAAAGTCAGTGAACAGCTACAGGCCAAAATGCCTA-TGAAAAAAGAAGCAAAACCTTCAGCTACCGGTAAAGTCATTGATAAAAAA-CTACCAAAACCTCTTGAAAAGGTACCTATGCTGGTGCCAGTGCCAGTGTC-TGAGCCAGTGCCAGAGCCAGAACCTGAGCCAGAACCTGAGCCTGTTAAA-GAAGAAAAACTTTCGCCTGAGCCTATTTTGGTTGATACTGCTAGCAATA-3 ) or the same region of the protein with arginine substitutions at all lysine residues (cyc allR ; 5 -AACCGGTCCGAAACCGTCGACATGTCGCATC-ACCATCACCATCACGGCTCGATGGCGCTCCGAGTCACGCGTAACTCGAGA-ATTAATGCTGAAAATAGAGCGAGAATCAACATGGCAGGCGCCAGGCGCG-TTCCTACGGCACCGGCGGCAACCTCCAGACCCGGGCTGAGGCCAAGAAC-AGCTCTTGGGGACATTGGTAACAGAGTCAGTGAACAGCTACAGGCCAGA-ATGCCTATGAGAAGAGAAGCAAGACCTTCAGCTACCGGTAGAGTCATTG-ATAGAAGACTACCAAGACCTCTTGAAAGGGTACCTATGCTGGTGCCAGT-GCCAGTGTCTGAGCCAGTGCCAGAGCCAGAACCTGAGCCAGAACCTGA-GCCTGTTAGAGAAGAAAGACTTTCGCCTGAGCCTATTTTGGTTGATACT-GCTAGCAATA-3 ) preceded by 6×His tag were synthesized (GenScript). Using restriction enzyme digestion with NheI and RsrII, fragments were subcloned into pFASTBac containing the carboxy terminus (125-433 amino acids) of cyclin B1. To generate cyc K64only , primers 5 -TCCAGACCCGGGCTGAGGCCAAGAACAGC-TCTTGGGGACATTGGTAACAGAGTCAGTGAACAGCTACAGGCC-3 and 5 -AATGACTCTACCGGTAGCTGAAGGTCTTGCTTCTTTTCTCATAGGCATTC-TGGCCTGTAGCTGTTCACTGAC-3 were used for an extension reaction and the resulting fragments cloned into XmaI and AgeI cleavage sites of pFASTBac carrying full-length cyc allR . Plasmids were verified by restriction enzyme mapping and sequencing. Baculoviruses were generated according to the Bac-to-Bac manual (Invitrogen). Wild-type cyclin B1 was 35 S-labelled in Sf9 cultures by resuspending cells (1.5×10 6 cells ml −1 ) in media containing 10% SF-900 II SFM and 90% SF-900 II SFM without methionine or cysteine (both from Invitrogen). Baculovirus was added to cells, along with 50 µCi of 35 S-labelled methionine and cysteine (NEG772; Perkin Elmer), and cyclin B1 expression was allowed for 2.5 days. CDK1 was expressed separately in Sf9 cells without radiolabelling and then combined with lysate from cells expressing cyclin B1 to allow formation of complex, which was then purified through Ni-NTA affinity and gel filtration chromatography. cycB1-NT (1-88) containing an HA tag at the N terminus and a 6×His tag at the C terminus was generated using PCR amplification with forward primer (5 -CCAGGACCATGGGTTACCCATACGA-TGTTCCAGATTACGCTGGCTCGATGGCGCTCCGAGTCACG-3 ) and reverse primer (5 -GGGAGCCTCGAGCTAGGGAGCGTGATGGTGATGGTGATGC-ATAGGTACCTTTTCAAGAGG-3 ). The resulting PCR product was digested with NcoI and XhoI for subcloning into pET28a. Plasmids were verified by restriction enzyme mapping and sequencing. For 35 S labelling in Escherichia coli, cultures (50 ml) were grown at 37 • C to D 600 nm = 0.8, then collected by centrifugation (3,700g for 15 min, at 4 • C) and resuspended in modified M9 medium (50 ml final volume). Cells were allowed to grow for 15 min at 37 • C before 5 mCi of Easy Tag L-[ 35 S]methionine (NEG709A005MC; Perkin Elmer) was added. Expression was induced with 0.5 mM IPTG for 2.5 h at 37 • C. Cells were ruptured in 5 ml g −1 of pellet guanidine-HCl lysis buffer (pH 8.0) and lysates rotated at 24 • C until the lysate became slightly translucent; approximately 45 min. Lysates were cleared by centrifugation and cycB1-NT was purified using Ni-NTA affinity chromatography (Qiagen). Eluted protein was desalted into XB buffer (100 mM KCl, 0.1 mM CaCl 2 , 1 mM MgCl 2 and 10 mM HEPES, at pH 7.8 with KOH), supplemented with 2% glycerol, protease inhibitors and phenylmethylsulfonyl fluoride, and stored at −20 • C.
Maltose-binding protein (MBP)-tagged E1 was expressed in E. coli inducing cultures at D 600 nm = 0.6 with 300 µM IPTG for 5 h at room temperature. Purification was carried out using a standard MBP purification protocol. For expression of His-tagged UBCH10 and His-tagged UBC4, bacterial cultures were induced at D 600 nm = 0.6 at 37 • C with 500 µM IPTG for 4 h. The enzymes were purified through Ni-NTA affinity and gel filtration chromatography. PET28a expressing human wild-type UBE2S was provided by M. Kirschner (Harvard Medical School, USA). Cultures were grown to D 600 nm = 0.4 and induced with 500 µM IPTG at 37 • C for 4 h. His-UBE2S was purified by Ni-NTA purification. GST-fusion proteins for Rpn10 and Rad23 were purified as reported previously 39, 58 .
Preparation of Xenopus egg extract. Interphase extract was prepared as described previously 57 but using 2 µg ml −1 calcium ionophore (A23187, Calbiochem) for egg activation. Interphase extract was induced to enter mitosis by addition of non-degradable cyclin B (MBP-90; ref. 59) as described previously 60 except that extracts were treated for 45-60 min before assay.
Reconstitution of ubiquitylation and degradation of cyclin B1.
Ubiquitylation reactions were carried out as described previously 11 , but to minimize loss of Cdc20, immunoprecipitated APC/C was washed quickly three times with XB containing 500 mM KCl, two times with XB and then three times with reaction buffer. Ubiquitylation reactions were carried out at 24 • C with agitation at 1,500 r.p.m. and contained APC/C on 30 µl beads, and 30 µl of a mix containing recombinant MBP-human E1 (1.3 µM), His-tagged UBCH10 or UBC4 (100 nM-4 µM), ubiquitin (118-145 µM) and 450-500 nM cyclin B1-CDK1 or cycB1-NT. For ubiquitin-receptor binding and degradation assays, reaction supernatants were combined with the first 20 µl of reaction buffer wash. For analysis of cyclin B1 ubiquitylation with different ubiquitins, entire reactions were processed for immunoblotting or autoradiography. Dried gels were analysed by phosphorimaging (Bio-Rad PMI); quantification was carried out with Quantity One software (Bio-Rad).
For binding experiments with ubiquitin receptors, cyclin B1-CDK1 was preubiquitylated with purified Xenopus APC/C, UBCH10 (3 µM) and ubiquitin (118 µM) for 90 min. Binding was carried out essentially as described previously 11 in the presence of 0.1% Tween 20. Supernatants were collected and mixed with the first wash to make the flow-through fraction. Beads were washed twice and diluted with SDS sample buffer to analyse the bound fraction.
For degradation assays with purified proteasomes, human proteasomes (10-20 nM), purified as reported previously 47 but non-UbVS treated, were incubated with cyclin B1-Ub n in buffer (50 mM Tris-HCl (pH 7.5), 5 mM MgCl 2 and 5 mM ATP; ref. 47 ) and incubated at 24 • C. Recombinant GST-USP14 (ref. 47) was incubated with proteasome for ∼5-10 min before initiating degradation. In experiments with USP14 inhibitor IU1 (ref. 47 ), GST-USP14 was pre-incubated with IU1 or dimethylsulphoxide for 5 min at 24 • C before adding proteasomes. For degradation of cycB1-NT, reactions (20 µl proteasome mix and 4 µl cycB1-NT-Ub n for each time point) were quenched with 81 µl of 32% trichloroacetic acid (TCA) and 20 µl bovine serum albumin (BSA; 10 mg ml −1 stock). For degradation of full-length cyclin B1, 90 µl proteasome mix was added to 10 µl cyclin B1-Ub n for each time point, and the reaction quenched with 112 µl pre-chilled 2% perchloric acid (PCA) and 12 µl of BSA (10 mg ml −1 stock). For 0 min time point, substrate and proteasome mixtures were individually added to acid. Following acid addition, samples were incubated on ice ≥30 min and centrifuged at 14,000g , at 4 • C. A fraction (50-80%) of supernatants and NaOH to neutralize TCA (or Tris Base to neutralize PCA) were added to Ultima Gold scintillation fluid (6013327, Perkin Elmer). A Packard DOI: 10.1038/ncb2425 scintillation counter was used to take measurements. Proteolysis was measured by release of TCA-soluble counts, and plotted as the percentage of input radiolabelled substrate. For degradation assays with unlabelled full-length cyclin B1, samples were analysed by anti-cyclin B1 immunoblot.
Cyclin B1 degradation in Xenopus extract. Degradation assays with nonubiquitylated cyclin B1 were carried out by adding ∼200-250 nM of cyclin B1 in 40 µl reactions, with extract constituting 75-80% of the total volume. Pre-treatment of extract with TAME or MG262 was done at 24 • C for 15 min. UbVS treatment was carried out for 30 min at 24 • C, with agitation. Extracts contained 100 µg ml −1 cycloheximide to prevent re-incorporation of free labelled amino acid. Degradation experiments were carried out at 24 • C, with agitation. Samples for proteolysis of unlabelled cyclin B1-CDK1 were processed for anti-cyclin B1 immunoblot. In degradation assays with 35 S-labelled cycB1-NT, reactions (3 µl per time point) were quenched with 97 µl of 20% TCA, vortexed and incubated on ice before centrifugation at 14,000g , at 4 • C. The radioactivity in the supernatant was measured by scintillation counting.
For degradation of pre-ubiquitylated cycB1-NT, interphase extract was pretreated with UbVS or buffer for 30 min at 24 • C with agitation and supplemented with 100 µg ml −1 cycloheximide. In experiments with IU1, IU1 or dimethylsulphoxide was added to extract for 15 min at 24 • C before addition of substrate. Extract (∼14 µl) was added to 4 µl of cycB1-NT-Ub n conjugates for each time point. Reactions were quenched with 107 µl of 20% TCA, vortexed and incubated on ice before centrifugation at 14,000g , at 4 • C for 30 min. A fraction of supernatants was combined with NaOH and scintillation fluid.
To deplete APC/C, 100 µl of interphase extract was mixed with 2 µg of anti-Cdc27 antibody coupled to 5 µl of Affiprep protein A beads and incubated at 4 • C for 3 h. Approximately 10 µl of pre-ubiquitylated radiolabelled cyclin B1 was added to 90 µl of APC/C-depleted extract. Reactions were incubated at 22 • C for the indicated times and stopped by the addition of an equal volume of chilled 2% PCA. Reactions were then incubated on ice for ≥30 min and centrifuged at 15,000 r.p.m. for 10 min, at 4 • C and radioactivity in the supernatant was measured by scintillation counting.
Immunodepletion of E2 enzymes. For UBE2S immunodepletion, 10 µg of anti-UBE2S antibody or control goat IgG antibody was bound to 25 µl UltraLink immobilized protein A/G and incubated with 250 µl extract at 4 • C for ∼1 h. For UBCH10 immunodepletion, 100 µl of anti-UbcX antibody or an equivalent amount of control rabbit IgG coupled to Affiprep protein A support was used to deplete 170 µl extract. Cyclin B1-CDK1 (∼200 nM) was added to E2-or control-depleted extract and analysis of the time course of degradation was carried out at 24 • C (1,250 r.p.m.) and the equivalent of 1 µl of extract was analysed by SDS-PAGE and anti-cyclin B1 immunoblot analysis. Depletion of UBE2S and UBCH10 was confirmed by western blotting using anti-UBE2S and anti-UBCH10, respectively. To confirm the efficiency of E2 depletion, extract was incubated with ubiquitin agarose, at a ratio of ∼10:1 (extract/resin). Ubiquitin agarose was pre-washed four times with 1× energy mix (for 20× stock: 150 mM creatine phosphate, 20 mM ATP, 2 mM EGTA and 20 mM MgCl 2 , at pH 7.7) in XB buffer (100 mM KCl). Extract and 2× energy mix were added to ubiquitin agarose and incubated with agitation at 24 • C for 45 min. Samples were centrifuged, extract was removed and ubiquitin agarose was washed once with a tenfold volume of 1× energy mix. Bound proteins were eluted by boiling in SDS sample buffer and analysed by immunoblotting. 
